Online inquiry

IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10557MR)

This product GTTS-WQ10557MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL23A gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_016584.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51561
UniProt ID Q9NPF7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10557MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14107MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aNGF75
GTTS-WQ2325MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ALXN6000
GTTS-WQ13239MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ5917MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CK-301
GTTS-WQ15333MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ11978MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MM-005
GTTS-WQ14323MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RG7414
GTTS-WQ3663MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1213790
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW